Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» AML
AML
Overcoming chemotherapy resistance in leukemia with a diarrhea drug from Merck
Fierce Biotech
Thu, 02/25/21 - 09:57 am
Merck
Dificid
AML
chemotherapy
Aptevo’s Phase I APVO436 Trial on Right Track Against AML
BioSpace
Tue, 11/3/20 - 09:36 pm
Aptevo
APVO436
immunotherapy
AML
clinical trials
Forma takes aim at Agios with new AML complete remission data
Endpoints
Mon, 10/26/20 - 11:01 am
Forma Therapeutics
sickle cell disease
clinical trials
Agios
AML
FDA grants full approval for Roche/AbbVie’s Venclexta in AML combination therapies
Pharmaforum
Mon, 10/19/20 - 10:56 am
Roche
Genentech
AbbVie
Venclexta
AML
clinical trials
FDA
Novartis vets get $35M to pluck one of the pharma giant’s abandoned drugs off the shelf and put it back into a clinical trial
Endpoints
Mon, 10/12/20 - 10:10 am
Novartis
KRP-203
Kyorin
Priothera Limited
AML
Bischofberger's Kronos files for IPO to run pivotal cancer trial
Fierce Biotech
Mon, 09/21/20 - 10:31 am
Kronos Bio
IPO
NASDAQ
AML
FDA approves Onureg as continued treatment for adults in first remission with AML
Pharmaceutical Business Review
Wed, 09/2/20 - 10:37 am
Bristol-Myers Squibb
Onureg
FDA
AML
Go or no go? A quiet month ahead for US approval verdicts
EP Vantage
Fri, 08/28/20 - 10:29 am
FDA
Bristol-Myers Squibb
CC-486
AML
Mallinckrodt
terlipressin
Mesoblast
Ryoncil
Vor Biopharma Snags $110 Million to Advance AML Treatment into the Clinic
BioSpace
Tue, 07/7/20 - 08:04 pm
Vor Biopharma
funding
stem cells
clinical trials
oncology
AML
EHA: AbbVie, Roche cement Venclexta's place in AML with survival win
Fierce Pharma
Sat, 06/13/20 - 11:32 pm
AbbVie
Roche
Venclexta
AML
EHA
Gilead’s newly bought immunotherapy drug scores at ASCO
MedCity News
Fri, 05/29/20 - 12:30 pm
Gilead Sciences
ASCO 2020
magrolimab
clinical trials
AML
MDS
How the pandemic helped secure a rare cancer drug for Menarini
Endpoints
Thu, 05/14/20 - 11:53 am
cancer
Menarini
Stemline
COVID-19
pandemic
Elzonris
AML
FDA accepts for priority review Bristol Myers Squibb’s application for CC-486 for maintenance treatment of adults in remission with AML
Pharmaceutical Business Review
Mon, 05/4/20 - 10:36 am
Bristol-Meyers Squibb
FDA
CC-486
AML
acute myeloid leukemia
Aveo gives up on ficlatuzumab in acute myeloid leukemia, citing COVID-19
Fierce Biotech
Mon, 03/30/20 - 10:33 am
Aveo Oncology
ficlatuzumab
AML
COVID-19
clinical trials
AbbVie announces positive topline results from phase 3 trial of VENCLEXTA, Azacitidine combo in AML
Pharmaceutical Business Review
Tue, 03/24/20 - 10:45 am
AbbVie
Venclexta
azacitidine
clinical trials
AML
AbbVie, Roche's Venclexta nails confirmatory combo trial in AML after flopping earlier study
Fierce Pharma
Mon, 03/23/20 - 11:53 am
AbbVie
Roche
Venclexta
AML
clinical trials
AbbVie, Roche's Venclexta endangers AML approval with flopped confirmatory trial
Fierce Pharma
Mon, 03/2/20 - 11:07 pm
AbbVie
Roche
Venclexta
AML
blood cancer
FDA
Study: Common, Inexpensive Drug Could Treat Resistant AML
BioSpace
Tue, 01/21/20 - 11:55 am
AML
cytarabine
hydroxyurea
Following Strong Phase III Results, BMS Plans to Seek Approval for AML Candidate CC-486
BioSpace
Tue, 12/10/19 - 11:38 pm
Bristol-Myers Squibb
CC-486
AML
This Small-Cap Biotech Rose as Much as 98.3% Today
Motley Fool
Mon, 12/9/19 - 11:30 pm
Forty Seven
ASH2019
magrolimab
monoclonal antibodies
AML
Pages
« first
‹ previous
1
2
3
4
5
6
next ›
last »